Axial length affects RNFL thickness profiles

Article

Axial length/refractive status affects the peripapillary retinal nerve fibre layer (RNFL) thickness profile in eyes measured by RTVue OCT.

Axial length/refractive status affects the peripapillary retinal nerve fibre layer (RNFL) thickness profile in eyes measured by RTVue OCT.

Dr Veysi öner et al., Department of Ophthalmology, Recep Tayyip Erdoğan University Medical School, Rize, Turkey, divided 98 subjects into three groups. The myopic group contained 35 patients, the emmetropic group had 30 patients and the hyperopic group consisted of 33 patients.

The RTVue was used to obtain RNFL thickness measurements for all octametric section parameters. Axial length and spherical equivalent values were also obtained for all subjects.

It was discovered that the RNFL thickness values were thinner in myopic eyes, compared to hyperopic eyes. Average RNFL thickness and RNFL thicknesses of the superotemporal, superonasal, inferotemporal and lower temporal sectors significantly differed between the myopic and emmetropic eyes.

The RNFL thicknesses of the upper temporal and inferonasal sectors were significantly different between hyperopic and emmetropic eyes. Average peripapillary RNFL thickness was negatively correlated with axial length, but this significant difference was eradicated after correction.

For the correct diagnosis of glaucoma the axial length-induced magnification effect must be corrected or the RTVue OCT database should consider axial length.

To read the abstract in the British Journal of Ophthalmology please click here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.